Collegium Pharmaceutical, INC 8-K filings

Collegium Pharmaceutical, Inc. has entered into an accelerated share repurchase agreement to buy back $50 million of its common stock as part of an ongoing repurchase program.

Collegium Pharmaceutical announced strong second-quarter 2026 results, with net revenues up 6% year-over-year, driven by significant growth in its ADHD portfolio, particularly JORNAY PM, and the successful acquisition of AZSTARYS.

Collegium Pharmaceutical, Inc. has finalized its acquisition of AZSTARYS from Corium Therapeutics Holdings, LLC for approximately $655.6 million, expanding its central nervous system drug offerings.

Collegium Pharmaceutical shareholders re-elected eight directors and ratified executive compensation and auditors at the 2026 Annual Meeting.

Collegium Pharmaceutical has finalized its acquisition of AZSTARYS, a CNS stimulant for ADHD, and has increased its 2026 financial outlook.

Collegium Pharmaceutical announced strong first quarter 2026 financial results, with net revenues up 9% year-over-year, driven by significant growth in JORNAY PM and its pain portfolio, while advancing its planned acquisition of AZSTARYS.

Collegium Pharmaceutical announced board changes including the nomination of Michael Donovan and the retirement of Dr. John Fallon.

Collegium Pharmaceutical will acquire AZSTARYS for $650 million in cash, strengthening its ADHD market position and accelerating growth.

Collegium Pharmaceutical, Inc. announced record full-year 2025 net revenues and adjusted EBITDA, driven by significant growth in Jornay PM and durable performance across its pain portfolio, while reaffirming strong 2026 guidance.

Collegium Pharmaceutical, Inc. announced its 2026 financial guidance, projecting increased product revenues and adjusted EBITDA, alongside a significant debt refinancing.

Collegium Pharmaceutical closed a new $980 million syndicated credit facility, refinancing existing debt and securing capital for future growth.

Collegium Pharmaceutical, Inc. reported record third-quarter 2025 financial results, driven by strong performance in its ADHD and pain portfolios, leading to a significant raise in its full-year 2025 guidance.

Collegium Pharmaceutical reported strong second quarter 2025 financial results, driven by record net revenue and growth in its ADHD and pain portfolios, leading to an increased full-year 2025 financial outlook.

Collegium Pharmaceutical, Inc. announced its Board of Directors has authorized a new share repurchase program of up to $150 million through December 31, 2026, to be funded by existing cash on hand.

Collegium Pharmaceutical's shareholders approved the 2025 Equity Incentive Plan at the Annual Meeting on May 15, 2025, along with the election of eight directors and other proposals.

Collegium Pharmaceutical executes an accelerated share repurchase agreement with Jefferies LLC to buy back $25 million of its common stock as part of a larger $150 million program.

Collegium Pharmaceutical announces a 23% year-over-year increase in Q1 2025 net revenue, driven by Jornay PM and its pain portfolio, while reaffirming its full-year 2025 guidance.

Collegium Pharmaceutical reports director resignations, the nomination of a new director, and the appointment of a new Executive Vice President and General Counsel.

Collegium Pharmaceutical announces record financial results for Q4 and full-year 2024, driven by strong performance in its pain portfolio and the addition of Jornay PM, and reaffirms its full-year 2025 guidance.

Collegium Pharmaceutical appoints Nancy Lurker to its board of directors, expanding the board from eight to nine members, effective February 4, 2025.

Collegium Pharmaceutical projects significant revenue and EBITDA growth for 2025, driven by the expansion of Jornay PM and continued performance of their pain portfolio.

Collegium Pharmaceutical finalized its acquisition of Ironshore Therapeutics on September 3, 2024, adding the ADHD medication Jornay PM to its portfolio.

Collegium Pharmaceutical reported record third-quarter revenue and appointed Vikram Karnani as its new CEO, effective November 12, 2024.

Collegium Pharmaceutical has completed its acquisition of Ironshore Therapeutics, adding the ADHD medication Jornay PM to its portfolio and establishing a presence in neurology.

Collegium Pharmaceutical reported a 7% year-over-year increase in net revenue to $145.3 million for Q2 2024, driven by record Belbuca sales and announced the acquisition of Ironshore Therapeutics.

Collegium Pharmaceutical will acquire Ironshore Therapeutics for $525 million in cash, with a potential $25 million milestone payment, expanding its portfolio into the neurology market with the addition of Jornay PM for ADHD.

Collegium Pharmaceutical has been granted a six-month extension of pediatric exclusivity for its Nucynta franchise by the FDA, pushing out patent expiration dates.

Collegium Pharmaceutical has appointed Michael Heffernan as Interim President and CEO, following the departure of Joseph Ciaffoni, effective May 24, 2024.

Collegium Pharmaceutical's 2024 Annual Meeting saw the re-election of all eight directors and approval of executive compensation and the appointment of Deloitte & Touche LLP as the company's independent auditor.

Collegium Pharmaceutical has entered into an accelerated share repurchase agreement with Jefferies LLC to buy back $35 million of its common stock as part of a larger $150 million program.